| Literature DB >> 31376328 |
Xingni Zhou1, Zhenghua Zhang2, Xiaohua Liang3.
Abstract
OBJECTIVE: Lung cancer has high incidence and mortality rate, and non-small cell lung cancer (NSCLC) takes up approximately 85% of lung cancer cases. This study is aimed to reveal miRNAs and genes involved in the mechanisms of NSCLC.Entities:
Keywords: Meta-Analysis; Non-Small Cell Lung Cancer; Protein Interaction; Regulatory Network; microRNA
Year: 2019 PMID: 31376328 PMCID: PMC6722447 DOI: 10.22074/cellj.2020.6281
Source DB: PubMed Journal: Cell J ISSN: 2228-5806 Impact factor: 2.479
Fig.1The results of enrichment analysis for the differentially expressed genes. A. Top five terms enriched for the up-regulated genes and B. Top five terms enriched for the down-regulated genes. The horizontal and vertical axes represent name of the enriched term and number of the genes involved in each term, respectively. BP; Biological process, CC; Cellular component, and MF; Molecular function.
Fig.2The significant modules identified from protein-protein interaction (PPI) network. A. The significant module a, B. The significant module b, C. The significant module c, D. The significant module d, and E. The significant module e. Red circles and green prismatic represent up-regulated genes and down- regulated genes, respectively.
Pathways enriched for the nodes in module a, b, c, d and e
| Module | Pathway ID | Pathway name | Count | P value | Genes |
|---|---|---|---|---|---|
| a | hsa03040 | Spliceosome | 5 | 1.53E-05 | PRPF8, SNRNP200, SNRPA, SNRPD2, SF3B2 |
| hsa03020 | RNA polymerase | 3 | 7.33E-04 | POLR2G, POLR2I, POLR2B | |
| hsa00240 | Pyrimidine metabolism | 3 | 7.54E-03 | POLR2G, POLR2I, POLR2B | |
| hsa00230 | Purine metabolism | 3 | 2.06E-02 | POLR2G, POLR2I, POLR2B | |
| hsa05169 | Epstein-Barr virus infection | 3 | 2.38E-02 | POLR2G, POLR2I, POLR2B | |
| hsa05016 | Huntington’s disease | 3 | 2.43E-02 | POLR2G, POLR2I, POLR2B | |
| a | hsa05166 | HTLV-I infection | 7 | 4.62E-04 | EGR1, FOS, ETS1, TP53, NFKBIA, TCF3, NFATC1 |
| hsa04660 | T cell receptor signaling pathway | 5 | 7.24E-04 | PTPRC, FOS, MAPK3, NFKBIA, NFATC1 | |
| hsa05161 | Hepatitis B | 5 | 2.57E-03 | FOS, MAPK3, TP53, NFKBIA, NFATC1 | |
| hsa04662 | B cell receptor signaling pathway | 4 | 2.61E-03 | FOS, MAPK3, NFKBIA, NFATC1 | |
| hsa04010 | MAPK signaling pathway | 6 | 3.22E-03 | FOS, MAPK3, TP53, DDIT3, NFATC1, DUSP6 | |
| hsa05133 | Pertussis | 4 | 3.31E-03 | FOS, IRF8, MAPK3, PYCARD | |
| hsa05215 | Prostate cancer | 4 | 5.19E-03 | MAPK3, TP53, NFKBIA, MTOR | |
| hsa04668 | TNF signaling pathway | 4 | 8.70E-03 | FOS, MAPK3, EDN1, NFKBIA | |
| hsa04151 | PI3K-Akt signaling pathway | 6 | 1.15E-02 | MAPK3, COL3A1, COL6A3, TP53, ITGB4, MTOR | |
| hsa04380 | Osteoclast differentiation | 4 | 1.54E-02 | FOS, MAPK3, NFKBIA, NFATC1 | |
| hsa04621 | NOD-like receptor signaling pathway | 3 | 2.06E-02 | MAPK3, PYCARD, NFKBIA | |
| hsa04921 | Oxytocin signaling pathway | 4 | 2.53E-02 | FOS, PRKAG1, MAPK3, NFATC1 | |
| hsa05210 | Colorectal cancer | 3 | 2.58E-02 | FOS, MAPK3, TP53 | |
| hsa05230 | Central carbon metabolism in cancer | 3 | 2.73E-02 | MAPK3, TP53, MTOR | |
| hsa05214 | Glioma | 3 | 2.81E-02 | MAPK3, TP53, MTOR | |
| hsa04920 | Adipocytokine signaling pathway | 3 | 3.23E-02 | PRKAG1, NFKBIA, MTOR | |
| hsa05140 | Leishmaniasis | 3 | 3.31E-02 | FOS, MAPK3, NFKBIA | |
| hsa05220 | Chronic myeloid leukemia | 3 | 3.40E-02 | MAPK3, TP53, NFKBIA | |
| hsa05132 | Salmonella infection | 3 | 4.40E-02 | FOS, MAPK3, PYCARD | |
| hsa04024 | cAMP signaling pathway | 4 | 4.49E-02 | FOS, MAPK3, NFKBIA, NFATC1 | |
| hsa04512 | ECM-receptor interaction | 3 | 4.79E-02 | COL3A1, COL6A3, ITGB4 | |
| hsa04510 | Focal adhesion | 4 | 4.95E-02 | MAPK3, COL3A1, COL6A3, ITGB4 | |
| c | hsa03022 | Basal transcription factors | 3 | 1.24E-04 | CCNH, ERCC3, GTF2B |
| hsa03420 | Nucleotide excision repair | 2 | 2.03E-02 | CCNH, ERCC3 | |
| d | hsa03010 | Ribosome | 5 | 1.44E-07 | MRPL24, MRPL1, MRPL13, RPL15, RPL27 |
| e | hsa05169 | Epstein-Barr virus infection | 5 | 9.95E-04 | POLR3K, SPI1, CD40, ENTPD1, POLR3E |
| hsa00240 | Pyrimidine metabolism | 4 | 1.93E-03 | POLR3K, DPYD, ENTPD1, POLR3E | |
| hsa00230 | Purine metabolism | 4 | 8.49E-03 | POLR3K, AK3, ENTPD1, POLR3E | |
| hsa04620 | Toll-like receptor signaling pathway | 3 | 2.73E-02 | IRAK4, TLR1, CD40 | |
ID; Identification, HTLV; Human T-lymphotropic virus type 1, TNF; Tumour-necrosis factor, NOD; Nucleotide oligomerization domain, and ECM; Extracellular matrix.
Fig.3miRNAs-gene regulatory network containing the top 10 miRNAs. Red circles, green prismatic and yellow triangles represent up-regulated genes, down- regulated genes and miRNAs, respectively.
Top 10 miRNAs and genes in the miRNA-gene regulatory network
| miRNA | Degree | Gene | Degree |
|---|---|---|---|
| hsa-miR-16-5p | 89 | HMGA1 | 11 |
| hsa-let-7b-5p | 84 | BAZ2A | 9 |
| hsa-miR-15a-5p | 44 | CALU | 9 |
| hsa-miR-15b-5p | 41 | BTG2 | 8 |
| hsa-let-7a-5p | 40 | SOD2 | 8 |
| hsa-miR-34a-5p | 37 | TP53 | 7 |
| hsa-miR-21-5p | 33 | UBN2 | 7 |
| hsa-miR-222-3p | 24 | CBX5 | 6 |
| hsa-miR-221-3p | 23 | ITGA2 | 6 |
| hsa-miR-372-3p | 23 | SLC10A7 | 6 |